Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 16c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($1.09), $0.16 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $72 thousand versus the consensus estimate of $141.08 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• ADP Employment Change (Aug) 38K vs 47K Expected
• Definitive Healthcare names Clay Ritchey as new CEO